SARTORIUS STED BIO (EPA:DIM) | Finanzwire

Basculer en Français

11016	Companies
241356	Keywords
169862	Articles
129899	Press releases

Home
Companies
SARTORIUS STED BIO

PRESS RELEASE

published on 07/02/2024 at 11:27, 2 years 2 months ago

Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech's half-year liquidity contract statement reveals significant shares and volume on June 30th, 2024. The company is a key player in the biopharmaceutical industry with a global presence

Liquidity Contract Shares Traded Volume Sartorius Stedim Biotech Biopharmaceutical Industry
PRESS RELEASE

published on 07/02/2024 at 11:25, 2 years 2 months ago

Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA reports half-year liquidity contract statement with details on executed shares, traded volumes, and resources, following AMF Decision N°2021-01

Shares Traded Volume Sartorius Stedim Biotech AMF Decision Half-year Liquidity Contract
BRIEF

published on 06/04/2024 at 10:15, 2 years 3 months ago

Publication of the Number of Shares and Voting Rights of Sartorius Stedim Biotech SA

Share Capital Voting Rights Actions AMF Sartorius Stedim Biotech
PRESS RELEASE

published on 06/04/2024 at 10:10, 2 years 3 months ago

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the number of shares and voting rights. The total number of shares is 97,330,405 with 165,579,822 total voting rights

Voting Rights Shares Sartorius Stedim Biotech SA Issued Capital French Regulatory News
BRIEF

published on 05/17/2024 at 19:37, 2 years 3 months ago

Sartorius Stedim Biotech unveils its strategy at Capital Markets Day

Business Strategy Webcast Sartorius Stedim Biotech Financial Forecast Capital Markets Day
PRESS RELEASE

published on 05/17/2024 at 19:32, 2 years 3 months ago

Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech presented its business strategy and goals during Capital Markets Day, reaffirming its 2024 forecast and medium-term ambitions up to 2028. Links to presentation and webcast provided for broad access

Business Strategy Webcast Forecast Sartorius Stedim Biotech Capital Markets Day
BRIEF

published on 05/02/2024 at 15:39, 2 years 4 months ago

Sartorius Stedim Biotech Announces Share and Voting Rights Update

Share Capital Voting Rights Financial News Corporate Governance Sartorius Stedim Biotech
PRESS RELEASE

published on 05/02/2024 at 15:34, 2 years 4 months ago

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the number of shares and voting rights comprising the issued capital as of April 30, 2024

Voting Rights Shares Sartorius Stedim Biotech SA Issued Capital French Regulatory News
BRIEF

published on 04/18/2024 at 07:07, 2 years 4 months ago

Sartorius Stedim Biotech reveals its results for the first quarter of 2024

Financial Results Biopharmaceutical Global Market Taking Orders Economic Projections
PRESS RELEASE

published on 04/18/2024 at 07:02, 2 years 4 months ago

Sartorius Stedim Biotech publishes unaudited first quarter results for 2024
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024, showing sales revenue of 667 million euros and order intake up 13.9 percent. Full-year outlook confirmed amidst global uncertainties

Order Intake Sartorius Stedim Biotech Sales Revenue First Quarter Results Full-year Outlook

Accesswire

Published on 09/17/2026 at 15:25, 22 minutes ago

AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 47 minutes ago

Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 47 minutes ago

ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 57 minutes ago

Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 14:47, 1 hour ago

Nextech3D.ai Announces CEO Evan Gappelberg Acquires 7.4 Million Shares

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 15:30, 17 minutes ago

Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/17/2026 at 15:08, 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/17/2026 at 15:07, 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/17/2026 at 15:07, 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/17/2026 at 15:06, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

Les Echos

Published on 09/16/2026 at 20:46, 19 hours 1 minute ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 22 hours 2 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 22 hours 2 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 8 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 21 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE